David Meek & Dr. Stacey Rifkin: A New Era in Sickle Cell Treatment | 13th & Park

Sickle cell disease has devastated families for generations — causing chronic pain, repeated hospitalizations, and shortened lives. On this episode of 13th & Park, we explore a potential breakthrough that is redefining what’s possible for patients living with this severe genetic condition. This conversation is hosted by Alison Anway, Chair of the Health Policy Group at Ballard Partners. She is joined by David Meek, CEO of Genetix Biotherapeutics, and Stacey Rifkin, a nationally respected pediatric hematologist who has spent her career treating children with sickle cell disease. Together, they discuss the science behind an FDA-approved gene therapy that treats sickle cell at the genetic level — offering patients a one-time, potentially transformative treatment. Listen to us on Spotify: https://open.spotify.com/show/2yqqjgPtA7NR2cJewPqbNQ?si=e9df5028fc0e4dd9 Listen to us on Apple Podcasts: https://podcasts.apple.com/us/podcast/13th-park/id1645880081 Follow Us! X: https://x.com/13thandPark IG: https://www.instagram.com/13th_and_park www.ballardpartners.com About 13th and Park: 13th and Park is a dynamic media platform produced by Ballard Partners. We bring you insightful discussions, expert interviews, and in-depth analysis on key issues shaping industries, policy, and business trends. Our content features thought leaders, industry experts, and policymakers exploring topics ranging from policy influence, business innovation, trade regulations, and more. Subscribe to stay updated on the latest videos, exclusive interviews, and expert insights shaping the future of business, policy, and public affairs. #SickleCell #GeneTherapy #Biotech #HealthcareInnovation #PrecisionMedicine #PublicHealth #FDA #MedicalBreakthrough #13thAndPark #HealthPolicy